KNSA
Kiniksa Pharmaceuticals Ltd
78.00$
+1.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 53.0% | 52.5% | 52.1% | 55.5% | 56.1% | 57.2% | 59.4% | 63.6% | 66.8% | 69.0% | 72.0% | 74.6% | |
| 24.4% | 20.5% | 27.1% | 18.3% | 17.5% | 31.6% | 26.2% | 29.0% | 24.5% | 21.7% | 23.0% | 19.6% | |
| 41.6% | 39.2% | 41.1% | 40.3% | 40.3% | 42.0% | 44.8% | 46.6% | 49.4% | 54.2% | 56.7% | 58.7% | |
| 0.6% | 4.0% | 3.1% | 3.8% | 4.5% | 7.2% | 6.7% | 4.8% | 7.3% | 2.0% | 2.8% | 2.6% | |
| 5.3% | 5.9% | 5.2% | 6.4% | 5.2% | 4.5% | 3.7% | 7.3% | 5.8% | 7.2% | 8.9% | 7.9% | |
| 2.8% | – | – | – | – | – | – | – | – | – | – | – | |
| 3.6% | 3.3% | 3.3% | 3.1% | 3.0% | 2.8% | 2.7% | 2.4% | 2.2% | 2.0% | 1.8% | 1.6% | |
| 16.1% | 16.6% | 16.9% | 19.8% | 21.3% | 24.5% | 23.7% | 25.1% | 24.8% | 25.7% | 26.6% | 27.0% | |
| 11.1% | 12.1% | 12.4% | 15.5% | 17.3% | 17.3% | 16.2% | 17.8% | 17.4% | 18.2% | 19.0% | 19.1% | |
| 0.5% | 0.4% | 0.4% | 0.4% | 0.4% | 0.3% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | 0.4% | |
| 0.2% | 1.6% | 1.1% | 1.4% | 1.5% | 0.4% | 0.3% | 1.4% | 0.9% | 0.3% | 3.0% | 1.4% | |
| 83.9% | 83.4% | 83.1% | 80.2% | 78.7% | 75.5% | 76.3% | 74.9% | 75.2% | 74.3% | 73.4% | 73.0% | |
| -104.2% | -90.8% | -95.4% | -92.1% | -92.2% | -89.8% | -85.5% | -74.8% | -66.9% | -60.5% | -53.3% | -46.2% | |
| 14.5% | 13.8% | 13.6% | 13.1% | 12.9% | 12.5% | 12.7% | 11.8% | 11.0% | 10.3% | 10.0% | 9.3% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.